Biogen
NEWS
Life sciences professionals don’t have to look far for opportunity in Genetown.
All of the recent problems have caused the company’s largest shareholder to push for a sale.
Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.
Another attempt at developing a treatment for Alzheimer’s has hit a wall.
We now turn to six MoneyShow.com contributors for their best ideas in biotechnology, a sector with both high risk and the potential for high rewards.
Investors love to speculate on M&A, and one of the hottest topics of speculation recently has been whether someone will buy BMS.
The Q3 earnings season is approaching its end with 81.2% of the S&P 500 companies having already released results.
ALZ’s researchers continue to see hope in Biogen’s aducanumab.
Biogen released its third-quarter financials yesterday, showing total revenues of $3.1B for the quarter, a 4 percent gain compared to the same period the previous year.
JOBS
IN THE PRESS